A broadly neutralizing anti-influenza antibody reveals ongoing capacity of haemagglutinin-specific memory B cells to evolve

Nature Communications

Volumn 7, Issue , 2016, Pages

  Fu, Ying ^a   Zhang, Zhen ^a   Sheehan, Jared ^a   Avnir, Yuval ^a   Ridenour, Callie ^a   Sachnik, Thomas ^a   Sun, Jiusong ^a   Hossain, M Jaber ^b   Chen, Li Mei ^b   Zhu, Quan ^a   Donis, Ruben O ^b   Marasco, Wayne A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; FC RECEPTOR; IGHV3 30 PROTEIN; IMMUNOGLOBULIN G1; INFLUENZA VIRUS HEMAGGLUTININ; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3114; NEUTRALIZING ANTIBODY; PROTEIN; TRYPSIN; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VLD94N PROTEIN; INFLUENZA VACCINE; PROTEIN BINDING;

ANTIBODY; CELLS AND CELL COMPONENTS; EXPERIMENTAL STUDY; GENETIC ANALYSIS; INFLUENZA; MUTATION; RODENT; VACCINE;

AIRWAY EPITHELIAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; CELL CULTURE; CELL ISOLATION; COMPETITIVE BINDING ASSAY; COMPLEMENTARITY DETERMINING REGION; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CROSS REACTION; CRYSTAL STRUCTURE; CYTOTOXICITY; DNA FLANKING REGION; EPITOPE MAPPING; FEMALE; FLOW CYTOMETRY; HEAVY CHAIN; HUMAN; HUMAN CELL; IC50; INFLUENZA A VIRUS; INFLUENZA A VIRUS (H3N2); INFLUENZA A VIRUS (H5N1); INFLUENZA A VIRUS (H7N7); INFLUENZA A VIRUS (H7N9); INFLUENZA B; LOW DRUG DOSE; MEMORY CELL; MOLECULAR EVOLUTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PERIPHERAL BLOOD MONONUCLEAR CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEROTYPE; SOMATIC HYPERMUTATION; VIRUS NEUTRALIZATION; WILD TYPE; ANIMAL; ANTIBODY AFFINITY; B LYMPHOCYTE; EVOLUTION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INFLUENZA; MOLECULAR MODEL; ORTHOMYXOVIRUS INFECTION; PHYLOGENY; PHYSIOLOGY; PROTEIN CONFORMATION; VETERINARY MEDICINE; VIROLOGY;

INFLUENZA A VIRUS; MUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; B-LYMPHOCYTES; BIOLOGICAL EVOLUTION; EPITOPE MAPPING; EPITOPES; GENE EXPRESSION REGULATION, VIRAL; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MODELS, MOLECULAR; ORTHOMYXOVIRIDAE INFECTIONS; PHYLOGENY; PROTEIN BINDING; PROTEIN CONFORMATION;

EID: 84987781434     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms12780     Document Type: Article

References (55)

1. WHO. WHO Influenza Fact Sheet No. 211, revised March 2003 (updated 19 October 2011). Available at http://www. who. int/mediacentre/factsheets/2003/fs211/en/(2011).
2. de Wit, E., Fouchier, R. A. Emerging influenza. J. Clin. Virol. 41, 1-6 (2008).
3. Webster, R. G. 1918 Spanish influenza: the secrets remain elusive. Proc. Natl Acad. Sci. USA 96, 1164-1166 (1999).
4. Bouvier, N. M., Palese, P. The biology of influenza viruses. Vaccine 26 (Suppl 4): D49-D53 (2008).
5. Nelson, M. I., Holmes, E. C. The evolution of epidemic influenza. Nat. Rev. Genet. 8, 196-205 (2007).
6. Tong, S. et al. New world bats harbor diverse influenza A viruses. PLoS Pathog. 9, e1003657 (2013).
7. Hay, A. J., Gregory, V., Douglas, A. R., Lin, Y. P. The evolution of human influenza viruses. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 356, 1861-1870 (2001).
8. Taubenberger, J. K., Kash, J. C. Influenza virus evolution, host adaptation, and pandemic formation. Cell Host Microbe 7, 440-451 (2010).
9. Parvin, J. D., Moscona, A., Pan, W. T., Leider, J. M., Palese, P. Measurement of the mutation rates of animal viruses: influenza A virus and poliovirus type 1. J. Virol. 59, 377-383 (1986).
10. Hensley, S. E. et al. Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science 326, 734-736 (2009).
11. WHO. Influenza at the Human-Animal Interface, monthly risk assessment summary 13 November 2015. Available at http://www. who. int/influenza/human-animal-interface/Influenza-Summary-IRA-HA-interface-13November-2015. pdf (2015).
12. Sui, J. et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16, 265-273 (2009).
13. Friesen, R. H. et al. New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets. PLoS ONE 5, e9106 (2010).
14. Ekiert, D. C. et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 333, 843-850 (2011).
15. Corti, D. et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850-856 (2011).
16. Dreyfus, C. et al. Highly conserved protective epitopes on influenza B viruses. Science 337, 1343-1348 (2012).
17. Nakamura, G. et al. An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies. Cell Host Microbe 14, 93-103 (2013).
18. Wyrzucki, A. et al. Alternative recognition of the conserved stem epitope in influenza A virus hemagglutinin by a VH3-30-encoded heterosubtypic antibody. J. Virol. 88, 7083-7092 (2014).
19. Wyrzucki, A., Bianchi, M., Kohler, I., Steck, M., Hangartner, L. Heterosubtypic antibodies to influenza A virus have limited activity against cell-bound virus but are not impaired by strain-specific serum antibodies. J. Virol. 89, 3136-3144 (2015).
20. Wu, Y. et al. A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus. Nat. Commun. 6, 7708 (2015).
21. Henry Dunand, C. J. et al. Preexisting human antibodies neutralize recently emerged H7N9 influenza strains. J. Clin. Invest. 125, 1255-1268 (2015).
22. Jin, A. et al. A rapid and efficient single-cell manipulation method for screening antigen-specific antibody-secreting cells from human peripheral blood. Nat. Med. 15, 1088-1092 (2009).
23. Smith, K. et al. Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigen. Nat. Protoc. 4, 372-384 (2009).
24. Kurosaki, T., Kometani, K., Ise, W. Memory B cells. Nat. Rev. Immunol. 15, 149-159 (2015).
25. Slifka, M. K., Antia, R., Whitmire, J. K., Ahmed, R. Humoral immunity due to long-lived plasma cells. Immunity 8, 363-372 (1998).
26. Purtha, W. E., Tedder, T. F., Johnson, S., Bhattacharya, D., Diamond, M. S. Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants. J. Exp. Med. 208, 2599-2606 (2011).
27. Kaji, T. et al. Both mutated and unmutated memory B cells accumulate mutations in the course of the secondary response and develop a new antibody repertoire optimally adapted to the secondary stimulus. Int. Immunol. 25, 683-695 (2013).
28. Jiang, N. et al. Lineage structure of the human antibody repertoire in response to influenza vaccination. Sci. Trans. Med. 5, 171-119 (2013).
29. Pappas, L. et al. Rapid development of broadly influenza neutralizing antibodies through redundant mutations. Nature. 516, 418-22 (2014).
30. Skehel, J. J., Wiley, D. C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 69, 531-569 (2000).
31. Klenk, H. D., Garten, W. Host cell proteases controlling virus pathogenicity. Trends Microbiol. 2, 39-43 (1994).
32. Lazarowitz, S. G., Goldberg, A. R., Choppin, P. W. Proteolytic cleavage by plasmin of the HA polypeptide of influenza virus: host cell activation of serum plasminogen. Virology 56, 172-180 (1973).
33. DiLillo, D. J., Tan, G. S., Palese, P., Ravetch, J. V. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcgammaR interactions for protection against influenza virus in vivo. Nat. Med. 20, 143-151 (2014).
34. Zhu, K. et al. Antibody structure determination using a combination of homology modeling, energy-based refinement, and loop prediction. Proteins 82, 1646-1655 (2014).
35. Lyskov, S., Gray, J. J. The RosettaDock server for local protein-protein docking. Nucleic Acids Res. 36, W233-W238 (2008).
36. Champ, P. C., Camacho, C. J. FastContact: a free energy scoring tool for protein-protein complex structures. Nucleic Acids Res. 35, W556-W560 (2007).
37. Li, G. M. et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc. Natl Acad. Sci. USA 109, 9047-9052 (2012).
38. Corti, D. et al. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 120, 1663-1673 (2010).
39. Avnir, Y. et al. Molecular signatures of hemagglutinin stem-directed heterosubtypic human neutralizing antibodies against influenza A viruses. PLoS Pathog. 10, e1004103 (2014).
40. Lingwood, D. et al. Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature 489, 566-570 (2012).
41. Odegard, V. H., Schatz, D. G. Targeting of somatic hypermutation. Nat. Rev. Immunol. 6, 573-583 (2006).
42. Allen, D. et al. Timing, genetic requirements and functional consequences of somatic hypermutation during B-cell development. Immunol. Rev. 96, 5-22 (1987).
43. Nachbagauer, R. et al. Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans. J. Virol. 88, 13260-13268 (2014).
44. Krammer, F., Pica, N., Hai, R., Margine, I., Palese, P. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J. Virol. 87, 6542-6550 (2013).
45. Yassine, H. M. et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat. Med. 21, 1065-1070 (2015).
46. Impagliazzo, A. et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349, 1301-1306 (2015).
47. Miller, M. S. et al. 1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. J. Infect. Dis. 207, 98-105 (2013).
48. Ross, T. M. et al. Influence of pre-existing hemagglutination inhibition titers against historical influenza strains on antibody response to inactivated trivalent influenza vaccine in adults 50-80 years of age. Hum. Vaccin. Immunother. 10, 1195-1203 (2014).
49. Keating, R. et al. The kinase mTOR modulates the antibody response to provide cross-protective immunity to lethal infection with influenza virus. Nat. Immunol. 14, 1266-1276 (2013).
50. Mannick, J. B. et al. mTOR inhibition improves immune function in the elderly. Sci. Transl. Med. 6, 268ra179 (2014).
51. Avnir, Y. et al. IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity. Sci. Rep. 6, 20842 (2016).
52. Yoon, A. et al. An Anti-influenza virus antibody inhibits viral infection by reducing nucleus entry of influenza nucleoprotein. PLoS ONE 10, e0141312 (2015).
53. Tiller, T. et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods 329, 112-124 (2008).
54. Reff, M. E. et al. Depletion of B cells in vivo by a chimeric mouse hsuman monoclonal antibody to CD20. Blood 83, 435-445 (1994).
55. Cheng, Z. J. et al. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies. J. Immunol. Methods 414, 69-81 (2014).